EXACT Sciences (EXAS) Given a $65.00 Price Target by Benchmark Analysts

Benchmark set a $65.00 price objective on EXACT Sciences (NASDAQ:EXAS) in a report published on Wednesday morning. The brokerage currently has a buy rating on the medical research company’s stock.

EXAS has been the topic of a number of other reports. Leerink Swann reissued an outperform rating and issued a $50.00 price objective (up from $45.00) on shares of EXACT Sciences in a research note on Thursday, September 21st. Zacks Investment Research raised shares of EXACT Sciences from a hold rating to a buy rating and set a $62.00 price objective on the stock in a research note on Tuesday. BidaskClub raised shares of EXACT Sciences from a hold rating to a buy rating in a research note on Thursday, December 21st. William Blair reissued a buy rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Finally, Canaccord Genuity reissued a buy rating and issued a $60.00 price objective (up from $45.00) on shares of EXACT Sciences in a research note on Tuesday, October 3rd. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $51.64.

EXACT Sciences (NASDAQ EXAS) traded up $1.11 during trading hours on Wednesday, hitting $48.79. 4,671,582 shares of the stock were exchanged, compared to its average volume of 2,570,000. The firm has a market cap of $5,840.00, a PE ratio of -42.43 and a beta of 0.68. EXACT Sciences has a fifty-two week low of $16.95 and a fifty-two week high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.07. The firm had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $65.03 million. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The firm’s revenue was up 158.4% on a year-over-year basis. During the same period in the prior year, the company earned ($0.36) EPS. analysts forecast that EXACT Sciences will post -1.09 EPS for the current year.

In other news, insider Kevin T. Conroy sold 134,057 shares of the stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $59.50, for a total transaction of $7,976,391.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin T. Conroy sold 125,402 shares of the stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $52.79, for a total transaction of $6,619,971.58. Following the transaction, the insider now owns 955,454 shares in the company, valued at $50,438,416.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 735,835 shares of company stock worth $40,961,278. 4.00% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in EXAS. Krilogy Financial LLC lifted its holdings in shares of EXACT Sciences by 1,460.0% during the 2nd quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after acquiring an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of EXACT Sciences by 17.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after acquiring an additional 600 shares during the period. Crow Point Partners LLC purchased a new position in shares of EXACT Sciences during the 4th quarter worth about $145,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after acquiring an additional 3,072 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of EXACT Sciences during the 3rd quarter worth about $183,000. Institutional investors and hedge funds own 82.39% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “EXACT Sciences (EXAS) Given a $65.00 Price Target by Benchmark Analysts” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2018/01/18/exact-sciences-exas-given-a-65-00-price-target-by-benchmark-analysts.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply